The clinical implications of weight gain in schizophrenia

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 7, 2001, Pages 32-37

  Kurzthaler, I ^a   Fleischhacker, W W ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; CLOZAPINE; HISTAMINE H1 RECEPTOR; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; RISPERIDONE; SERTINDOLE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; ZIPRASIDONE; ZOTEPINE;

BEHAVIOR THERAPY; CAREGIVER; CLINICAL PRACTICE; CLINICAL TRIAL; DIET THERAPY; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG MONITORING; FOOD INTAKE; HUMAN; LABORATORY TEST; META ANALYSIS; MORBIDITY; MORTALITY; OBESITY; PATIENT COMPLIANCE; PATIENT MONITORING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SCREENING TEST; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTIPSYCHOTIC AGENTS; APPETITE REGULATION; BEHAVIOR THERAPY; DIET; FEMALE; HEALTH BEHAVIOR; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; OBESITY; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS; QUALITY OF LIFE; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 0035040066     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Medical illness in patients with schizophrenia
2. Some adverse effects of antipsychotics: Prevention and treatment
3. Extrapyramidal syndromes: Epidemiology, pathophysiology and the diagnostic dilemma
4. Drug treatment of schizophrenia in the 1990s: Achievements and future possibilities in optimising outcomes
5. Body weight induced by antipsychotic drugs: Mechanisms and management
6. Weight changes with depot neuroleptic maintenance therapy
7. Weight gain during neuroleptic treatment
8. The distribution of body mass index among individuals with and without schizophrenia
9. Prevalence of obesity in patients receiving depot antipsychotics
10. Antipsychotic-induced weight gain: A comprehensive research synthesis
11. Weight gain: Side effect of atypical neuroleptics?
12. Olanzapine increases weight and serum triglyceride levels
13. Weight gain induced by olanzapine
14. Dosing the antipsychotic medication olanzapine
15. The pharmacology of weight gain with antipsychotics
16. Serotonergic mechanisms in human feeding: The pharmacological evidence
17. 2C serotonin receptors
18. Receptor-binding profiles of neuroleptics
19. Body weight and leptin plasma levels during treatment with antipsychotic drugs
20. Gewichtszunahme, Anstieg von körpeffettanteil und serumleptinspiegel bei patienten unter therapie mit olanzapin
21. Leptin: The voice of the adipose tissue
22. Physical and psychological consequences of weight gain
23. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report
24. Novel antipsychotics and new onset diabetes
25. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications
26. Primary prevention of coronary heart disease: Guidance from Framingham: A statement for healthcare professionals from the AHA Task Force on Risk Reduction
27. Somatic morbidity in schizophrenia: A case control study
28. Excess mortality of mental disorder
29. Prevalence of smoking among psychiatric outpatients
30. Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects
31. Nutrition-related risk factors in the elderly
32. Unrecognized physical illness prompting psychiatric admission: A prospective study
33. The physical examination in psychiatry
34. An evaluation of the performing and recording of physical examination by psychiatric trainees
35. Psychiatrists' attitudes to physical examination of new out-patients with major depressive disorder
36. Assessing the physical health of psychiatric patients
37. Improvements in practice from assessing standards of recording psychiatric case notes
38. Medical evaluation of psychiatric patients
39. Pharmacological treatment of schizophrenia: A review
40. Weight gain and hormone replacement therapy: Are women's fears justified?
41. Weight changes during and after hospital treatment
42. Olanzapine: A pharmacoeconomic review of its use in schizophrenia
43. A comparative review of new antipsychotics
44. The association between weight change and psychological well-being in women
45. Neuroleptics and quality of life: A patient survey
46. Social and economic consequences of overweight in adolescence and young adulthood
47. Obesity stigmatization and coping: Relation to mental health symptoms, body image, and self-esteem
48. Drug-induced weight gain
49. Drug-produced obesity: Experiences with chlorpromazine, perphenazine and clopenthixol
50. Nonpharmacologic and pharmacologic management of weight gain
51. Obesity: A time bomb to be defused